Immunotherapy After Surgery Shows Durable Results in High-Risk Esophageal Cancer
A phase II trial found that adjuvant sintilimab monotherapy after surgery met its primary efficacy endpoint with 87.5 percent one-year ...
A phase II trial found that adjuvant sintilimab monotherapy after surgery met its primary efficacy endpoint with 87.5 percent one-year ...
A network meta-analysis of 58 phase III trials covering 36,664 patients ranks the safety of 20 immune checkpoint inhibitors combined ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine